Aquestive Therapeutics has maintained its fair value estimate at $9.08 per share, with a steady discount rate of 6.78% and solid revenue growth projections. Recent bullish sentiment has been fueled by key developments, including the extension of Anaphylm’s patent protection and a smooth regulatory path forward. Stay tuned to learn how these factors could further shape the evolving narrative around Aquestive Therapeutics in the coming months.

???? Bullish Takeaways

Recent analyst actions indicate strengthening positive sentiment for Aquestive Therapeutics, with multiple firms raising price targets and reiterating Outperform ratings.

Citizens JMP increased its price target from $9 to $12, highlighting two additional Anaphylm patents that extend brand exclusivity through at least 2037. The firm views these patents as meaningfully value accretive and emphasizes the company's solid execution in intellectual property protection and pipeline advancement.

Oppenheimer also raised its price target, moving from $7 to $8, and maintains an Outperform view. Oppenheimer credits Aquestive’s positive regulatory milestones, specifically the FDA’s decision not to require an advisory committee meeting for Anaphylm, as a catalyst that increased investor confidence and improved the likelihood of product approval. The substantial share price reaction further reflects bullish momentum.

LifeSci Capital initiated coverage of Aquestive Therapeutics with an Outperform rating and established a $10 price target, adding to the breadth of optimism for the company’s growth trajectory.

Analysts reward Aquestive’s demonstrated progress in regulatory pathways and intellectual property management as key growth drivers. Some also note the importance of monitoring near-term risks and execution on commercialization.

???? Bearish Takeaways

Across recent coverage, few explicit bearish reservations have been detailed by analysts. None of the firms cited downgraded or initiated a neutral or underperform view in the coverage reviewed.

Nonetheless, implicit cautions remain regarding near-term execution risks and whether projected upside may already be reflected in the current valuation, particularly following significant share gains.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Oppenheimer raised its price target for Aquestive Therapeutics to $8 from $7 after the FDA decided not to require an Advisory Committee meeting for Anaphylm. This resulted in a significant share price increase.

The FDA informed Aquestive Therapeutics that an Advisory Committee meeting will not be required for Anaphylm, reducing regulatory hurdles and clearing a path toward potential approval.

Aquestive Therapeutics completed a follow-on equity offering and secured $85 million through the sale of 21,250,000 shares of common stock at $4 per share.

The company reaffirmed its full-year 2025 earnings guidance and is projecting total revenue between $44 million and $50 million.

The Fair Value Estimate remains unchanged at $9.08 per share.

The Discount Rate is steady at 6.78%, indicating no change in risk assessment.

The Revenue Growth projection is essentially unchanged at approximately 43% year over year.

The Net Profit Margin estimate has decreased very slightly to 22.06% from 22.09%.

The Future P/E Ratio has risen marginally from 47.29x to 47.34x.

Narratives are a smarter way to invest, letting you see the story behind the numbers. On Simply Wall St’s Community page, millions of investors use Narratives to connect a company’s journey, from products to patents to financial forecasts, all the way to fair value. Narratives help you know when to buy or sell by comparing fair value with the latest price, and always update as new earnings or news emerge.

Follow the original Narrative for Aquestive Therapeutics to stay ahead on:

How extended Anaphylm patent protection and FDA milestones are shaping near-term approvals and future revenue growth

The impact of market demand for needle-free drug delivery and Aquestive’s strategies for rapid product adoption

Risks to the company’s outlook, including market competition, payer access, and ongoing funding needs

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AQST.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com